Drug intelligence / Profile preview

withanolide E

Development stage
Preclinical
Lead developer
University of Arizona
Modality
Small Molecules
01

Overview

Withanolide E is a natural steroidal lactone isolated from the plant *Physalis peruviana* (Cape gooseberry). It has been identified as a potent sensitizer of various human cancer cell lines, particularly renal cell carcinoma and melanoma, to apoptosis induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and the TLR3 ligand poly(I:C). Its mechanism of action involves the reduction of cellular levels of the antiapoptotic protein c-FLIP (both long and short isoforms) and the enhancement of caspase-8 activation at the death-inducing signaling complex (DISC). Unlike proteasome inhibitors such as bortezomib, withanolide E does not inhibit the proteasome, and its sensitizing effects are dependent on cellular redox changes, as they can be blocked by antioxidants like n-acetyl cysteine. It belongs to the 17-beta-hydroxywithanolide class of compounds and serves as a scaffold for the development of more potent apoptosis-inducing agents.

Other names
WE
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)HSP90 (Heat shock protein 90 chaperone complex)CASP8 (Caspase-8)CFLAR (CASP8 and FADD-like apoptosis regulator)

Beyond the preview

Go deeper on withanolide E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on withanolide E.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call